Not Yet RecruitingNot Applicable

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

50 participantsStarted 2026-01-30

Plain-language summary

This study is a prospective, single-center, observational study of patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Minimal residual disease (MRD) detection is used to investigate the actual efficacy responses of mHSPC patients with different gene mutation characteristics to treatment regimens. Factors influencing efficacy are further analyzed to provide a basis for the precise clinical diagnosis and treatment of mHSPC patients.

Who can participate

Age range18 Years – 85 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 years and younger than 85 years;
✓. Patients diagnosed with prostate acinar adenocarcinoma, ductal adenocarcinoma, or intraductal carcinoma by pathological histology;
✓. Patients with clear distant metastases found by imaging (in accordance with RECIST criteria);
✓. Patients with locally advanced (N1) and metastatic (M1) prostate cancer at diagnosis.
✓. Patients who have not received endocrine therapy or other systemic anti-tumor treatments in the past;
✓. ECOG score of 0-2 points, with an expected survival period of more than 6 months;
✓. Patients with normal organ function;
✓. Routine blood test (no blood transfusion or blood products within 14 days):

What they're measuring

minimal residual disease(MRD) positive rate

Timeframe: baseline

Trial details

NCT IDNCT07112612

SponsorAnhui Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-30

View on ClinicalTrials.gov More MRD trials